Citi analyst Andrew Baum opened a positive catalyst watch on Roche (RHHBY) shares saying he expects CD20-TCB data at the American Society of Hematology meeting to report overall response rate and complete response “materially higher” than the 38% and 24% reported in the abstract as doses are escalated from 1800 microgams up to 60 milligrams. Further, unlike the Genentech and Regeneron (REGN) antibodies, Roche has seen no neurotoxicity with their CD20-TCB, says Baum. The analyst anticipates that Roche’s CD20-TCB will look superior to Genentech’s CD20/CD3 and Regeneron’s REGN1979 on safety. He keeps a Neutral rating on Roche.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.